Handelsavisen
prelaunch
69
6942.T Tokyo Stock Exchange Drug Retailers

Sophia Holdings Co Ltd

¥1 306,00
Open in Charts → Attach watcher ⌖
JPY
Set alert
Last 30 days
1D5D1M3M6MYTD1Y5YMax
Live price chart loads from the market-data widget.
Mcap
P/E
EV / Rev
Div yield
0,00 %
Op margin
-3,1 %
ROE
-5,5 %
Net margin
-6,9 %
Debt / equity
1,15
Beta
52w range
Volume
Day range
Prev close
Open
Next earnings
Ex-dividend
TR 1Y
About

Sophia Holdings Co Ltd operates in the drug retailing industry, primarily generating revenue through the sale of pharmaceuticals and related products.

Business. Sophia Holdings Co Ltd (6942.T) is a drug retailer headquartered in Japan and listed on the Tokyo Stock Exchange. The company operates within the Food & Drug Retailing industry, generating revenue primarily through the sale of products. Specific details regarding operating segments and geographic revenue mix are not available.

Classification92 %
SectorConsumer Non-Cyclicals
Business sectorFood & Drug Retailing
IndustryDrug Retailers
ActivityFood & Drug Retailing
Generated · model-assisted
Sell-side consensus
consensus pending
— buy— hold— sell
Avg 12m price target
Upcoming events
— missing data
See all catalysts →

At a glance

Score
not yet scored
Valuation
valuation pending
Analysts
not yet wired
Ownership
not yet wired
Profitability
-5,5 %
return on equity
Quality
not yet scored

What drives this business

The watch-list the newsroom runs for this company — derived from its sector path, sharpened layer by layer. Not investment advice.

— missing data

News & coverage

0
  • No recent newsroom coverage mentioning 6942.
  • Sector rotation

    Sector1D1Mvs mkt
    Materials+2,3 %+6,6 %+1,7 %
    Communication Services+2,2 %−5,5 %+1,6 %
    Energy+0,6 %+3,3 %+0,0 %
    Health Care+0,6 %−0,8 %+0,0 %
    Information Technology+0,6 %+6,7 %+0,0 %
    Consumer Discretionary+0,4 %+7,6 %−0,2 %
    Financials−0,3 %−2,8 %−0,9 %
    Consumer Staples · THIS SECTOR−0,4 %+2,5 %−1,0 %
    Real Estate−0,7 %+10,9 %−1,3 %
    Industrials−1,9 %−3,1 %−2,5 %
    Utilities−1,9 %+28,2 %−2,5 %

    Developing storylines

    No tracked sagas currently linked to 6942.T. Browse all sagas →

    Analysis

    AI analysis
    Generated · analysis pipeline · tier hybrid · as of 2026-08-04 ↑ At a glance

    Opportunity

    — missing data

    Upcoming catalysts

    Scheduled public events. Informational only — not investment advice.

    • Macro
    • Rate decisionBank of England rate decision (press conf.)2026-08-06 · GB
    • Rate decisionReserve Bank of Australia rate decision (press conf.)2026-08-12 · AU
    • Rate decisionNorges Bank rate decision (press conf.)2026-08-20 · NO
    • Rate decisionSveriges Riksbank rate decision (press conf.)2026-09-03 · SE
    • Rate decisionBank of Canada rate decision (press conf.)2026-09-09 · CA
    • Rate decisionEuropean Central Bank rate decision (press conf.)2026-09-10 · EU
    • Macro & political
    • ElectionSE Swedish Election2026-09-14 · SE
    • ElectionUS U.S. Midterms2026-11-03 · US
    • ElectionFR French Legislative2027-06-01 · FR

    Pre-earnings brief

    — missing data

    Signals & dispatch

    peak dispatch · —

    Composite-score breakdown

    Synthesis

    Business

    Sophia Holdings Co Ltd (6942.T) is a drug retailer headquartered in Japan and listed on the Tokyo Stock Exchange. The company operates within the Food & Drug Retailing industry, generating revenue primarily through the sale of products. Specific details regarding operating segments and geographic revenue mix are not available.

    Classification92 %
    SectorConsumer Non-Cyclicals
    Business sectorFood & Drug Retailing
    IndustryDrug Retailers
    ActivityFood & Drug Retailing
    AI synthesis
    GENERATED

    Sophia Holdings Co Ltd has a liquidity position that is characterized by a current ratio of 1.54, indicating that the company has sufficient current assets to cover its current liabilities. The company's cash and equivalents amount to 2,813,879,000 JPY, which is partially offset by long-term debt of 3,229,387,000 JPY, resulting in a negative net cash position. This suggests that the company may need to manage its debt obligations carefully to maintain liquidity.

    In terms of profitability, Sophia Holdings Co Ltd reported a net loss of 155,830,000 JPY and an operating loss of 69,097,000 JPY, indicating a challenging financial performance. The return on equity (ROE) is -5.55%, and the return on assets (ROA) is -1.87%, both of which are below the industry median for drug retailers. These metrics suggest that the company is not generating returns that meet industry expectations.

    The company's revenue is concentrated in the drug retailing segment, with no disclosed geographic diversification in the provided data. This lack of geographic diversification could expose the company to regional economic fluctuations and regulatory changes that may impact its operations and revenue.

    Looking at the growth trajectory, the company's recent financial performance shows a decline in profitability, with a net loss and operating loss reported. The capital expenditure of -32,102,000 JPY indicates that the company is not investing heavily in new projects or infrastructure, which may affect its long-term growth potential. The operating cash flow of 775,335,000 JPY provides some positive cash generation, but it is not sufficient to offset the net loss and debt obligations.

    The risk assessment for Sophia Holdings Co Ltd indicates a medium liquidity risk and a low dilution risk. The company's debt-to-equity ratio of 1.15 suggests a moderate level of leverage, which could increase financial risk if interest rates rise or if the company's earnings decline further. The key flag of negative net cash after subtracting total debt highlights the need for careful debt management to avoid liquidity constraints.

    Recent events and filings do not provide specific details on new initiatives or strategic changes for Sophia Holdings Co Ltd. The company's financial performance and risk profile suggest that it may need to focus on improving profitability and managing its debt to ensure long-term stability.

    Key takeaways
    • Sophia Holdings Co Ltd is experiencing a net loss and operating loss, indicating a challenging financial performance.
    • The company's liquidity position is moderate, with a current ratio of 1.54 and a negative net cash position after subtracting total debt.
    • The return on equity and return on assets are below industry medians, suggesting underperformance relative to peers.
    • The company's revenue is concentrated in the drug retailing segment, with no disclosed geographic diversification.
    • The company's capital expenditure is negative, indicating a lack of investment in new projects or infrastructure.

    Bull / Bear case

    Generated · model-assisted
    BULL CASE · 3

    Long-term debt decreased significantly from 4.67 billion JPY in 2021 to 2.31 billion JPY in 2025.

    The company maintains positive free cash flow of 171.6 million JPY in fiscal year 2025.

    Capital expenditure relative to revenue is above the drug retailer cohort median, indicating efficient investment.

    BEAR CASE · 1

    The company faces high credit risk and medium liquidity risk according to risk flag assessments.

    In focus — financials by report

    Quarterly
    Annual
    QUARTERLYFiled 2026-02-13
    Q4 2025 · Quarter highlights

    Revenue ¥2.14B, −0,1% YoY; Operating income −82,7% YoY.

    Revenue¥2.14B−0,1 % YoY
    Operating income¥81.1M−82,7 % YoY
    Net income¥36.1M−75,7 % YoY
    Free cash flow
    EPS
    Operating cash flow
    Financials
    Income statement
    Revenue¥2.14B
    Gross profit¥788.7M
    Operating income¥81.1M
    Net income¥36.1M
    Margins
    Gross margin36.9%
    Operating margin3.8%
    Net margin1.7%
    FCF margin
    Balance sheet
    Total assets¥6.91B
    Total liabilities¥3.85B
    Total equity¥3.06B
    Cash & equivalents¥1.84B
    Long-term debt¥1.77B
    P&L flow · revenue → net income
    Revenue ¥2.14BOperating costs ¥2.06BTax ¥45.0MNet income ¥36.1M
    Highlights
    • Revenue ¥2.14B, −0,1% YoY
    • Operating income −82,7% YoY
    • Net income −75,7% YoY
    • Net margin 1.7%

    Valuation TTM

    Market price
    ¥1 306,00
    Market cap
    Enterprise value
    P/E
    Non-GAAP P/E
    EV / Revenue
    EV / Op income
    EV / OCF
    P / B
    P / Tangible book
    Tangible book
    ¥2.81B
    Net cash
    -¥415.5M
    Current ratio
    1.5
    Debt / equity
    1.1
    ROA
    -1.9%
    ROE
    -5.5%
    Cash conversion
    -498.0%
    CapEx / revenue
    -1.4%
    SBC / revenue
    Dilution ratio
    0.0%

    Revenue by segment

    Market share

    — missing data

    Business relationships

    — missing data

    Supply chain

    — missing data

    Peer comparison

    — missing data

    Market position

    Stress test

    — missing data

    Predictor forecast

    Options

    — missing data

    Short squeeze

    — missing data

    Earnings-call key lines

    — missing data

    Estimate revisions

    consensus EPS · 26-week trend
    — missing data

    Sell-side observations

    — missing data

    Themes

    — missing data

    ESG

    — missing data

    Risk factors

    Dilution riskLow
    Liquidity riskMedium
    Filing-based flags
    • Net cash is negative after subtracting total debt.

    Benchmarks vs cohort

    Op Margin-3,1 %Bottom quartile
    Net Margin-6,9 %Bottom quartile
    ROE-5,5 %Bottom quartile
    Capex / Rev-1,4 %Above median
    D/E1,15Below median
    Cash Conv-4,98Bottom quartile

    Corporate actions / M&A

    — missing data

    FX exposure

    — missing data

    Comparable transactions

    — missing data

    Derivatives & instruments

    — missing data

    Actions

    Ask Handelsavisen

    — missing data
    Data sources
    • Market data
    • Market data cache
    • Issuer disclosures
    • Public news
    • Earnings transcripts
    • Consensus estimates
    • ESG data
    How metrics are computed
    • Dilution Ratio
      (shares_outstanding_diluted - shares_outstanding_basic) / shares_outstanding_basic
    • Net Cash
      cash_and_equivalents + short_term_investments - short_term_debt - long_term_debt
    • Capex To Revenue
      capital_expenditure / revenue
    • Return On Equity
      net_income / total_equity
    • Debt To Equity
      (short_term_debt + long_term_debt) / total_equity
    • Cash Conversion Ratio
      operating_cash_flow / net_income
    Source documents
    • Sophia Holdings Co Ltd Market data — financials · 2026-05-27
    • Sophia Holdings Co Ltd Market data — analyst estimates · 2026-05-27

    Ownership & reference

    Insider activity

    — missing data

    Short positioning

    — missing data

    Geographic breakdown

    — missing data
    Listings · one canonical issuer all listings resolve to the canonical
    6942.TCanonical
    Tokyo Stock Exchange · JPY

    Intel & risk

    peak dispatch · —
    OSINT findings
    Dilution riskLow
    Liquidity riskMedium
    Net cash is negative after subtracting total debt.

    Evidence & claims

    From filings & derived data
    — missing data

    The Thread

    Everything we know, in order
    2026-02-13 08:00 UTCEARNINGSQuarterly results — Q4 2025 Revenue JPY 2.14B · Net JPY 36.1M
    2025-11-14 08:00 UTCEARNINGSQuarterly results — Q3 2025 Revenue JPY 2.03B · Net JPY -9.3M
    2025-08-14 08:30 UTCEARNINGSQuarterly results — Q2 2025 Revenue JPY 1.98B · Net JPY 9.7M
    2025-05-15 08:30 UTCEARNINGSAnnual results — FY 2025 Revenue JPY 8.36B · Net JPY 95.3M
    2025-02-14 08:00 UTCEARNINGSQuarterly results — Q4 2024 Revenue JPY 2.14B · Net JPY 148.4M
    2024-11-14 08:00 UTCEARNINGSQuarterly results — Q3 2024 Revenue JPY 2.11B · Net JPY 11.4M
    2024-08-14 11:30 UTCEARNINGSQuarterly results — Q2 2024 Revenue JPY 2.07B · Net JPY 74.4M
    2024-05-15 11:30 UTCEARNINGSQuarterly results — Q1 2024 Revenue JPY 2.25B · Net JPY -155.8M
    2024-05-15 11:30 UTCEARNINGSAnnual results — FY 2024 Revenue JPY 9.03B · Net JPY 230.1M
    2023-05-15 11:30 UTCEARNINGSAnnual results — FY 2023 Revenue JPY 9.42B · Net JPY 21.1M
    2022-05-13 12:30 UTCEARNINGSAnnual results — FY 2022 Revenue JPY 11.78B · Net JPY 613.3M
    2021-05-14 12:30 UTCEARNINGSAnnual results — FY 2021 Revenue JPY 11.38B · Net JPY 501.9M
    The entity's full life in the product — typed, chronological, joined across Newspaper, Platform and Data. Our memory, made visible.
    Sources filings · IR · transcripts · market data · tier hybrid · as of 2026-08-04 Market data · Issuer disclosures · Public news · Earnings transcripts · Consensus estimates · ESG data Premium coverage